Heron Therapeutics Inc. (NASDAQ:HRTX) shares traded down 0.9% during trading on Monday . The company traded as low as $18.47 and last traded at $18.51, with a volume of 219,909 shares changing hands. The stock had previously closed at $18.68.

A number of research firms have weighed in on HRTX. Jefferies Group reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Cowen and Company reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Saturday. Cantor Fitzgerald reiterated a “buy” rating and set a $41.00 target price on shares of Heron Therapeutics in a research note on Friday, June 24th. Leerink Swann reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Finally, Noble Financial reiterated a “buy” rating and set a $51.00 target price on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $51.50.

The company has a 50-day moving average of $18.90 and a 200-day moving average of $19.81.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.92). On average, analysts anticipate that Heron Therapeutics Inc. will post ($3.57) EPS for the current year.

In other Heron Therapeutics news, President Robert Rosen sold 200,000 shares of the firm’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $23.23, for a total transaction of $4,646,000.00. Following the transaction, the president now directly owns 178,968 shares of the company’s stock, valued at approximately $4,157,426.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Other hedge funds recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of Heron Therapeutics during the fourth quarter valued at approximately $3,010,000. California Public Employees Retirement System boosted its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares during the period. Oxford Asset Management bought a new stake in shares of Heron Therapeutics during the fourth quarter valued at approximately $2,210,000. Swiss National Bank bought a new stake in shares of Heron Therapeutics during the fourth quarter valued at approximately $1,100,000. Finally, Turner Investments L.P. boosted its stake in shares of Heron Therapeutics by 19.7% in the fourth quarter. Turner Investments L.P. now owns 106,080 shares of the biotechnology company’s stock valued at $2,832,000 after buying an additional 17,470 shares during the period.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.